This webinar explores the groundbreaking effects of Dapagliflozin on major adverse kidney and cardiovascular events in both diabetic and non-diabetic patients with CKD. Participants will gain a comprehensive understanding of the latest evidence from clinical trials examining the role of Dapagliflozin in reducing the risk of progression to kidney failure, heart failure, and other major cardiovascular events in CKD patients. Designed for healthcare professionals, this webinar provides practical insights into integrating Dapagliflozin into treatment plans to optimize outcomes for patients with CKD, particularly those at risk for cardiovascular complications.